Polaris Partners, formerly Polaris Venture Partners, focuses on early-stage investments in disruptive opportunities across the healthcare, life sciences, and technology sectors. The firm also operates specialized funds, including the Polaris Growth Fund for profitable, founder-owned technology companies and the Polaris Innovation Fund for early-stage academic research with commercial potential.
33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 33% year-over-year (4 deals in the last 12 months). Average disclosed round size is $74.8M (across 55 rounds with reported amounts).
Portfolio
58
Fund Size
$5B
Top Stage
Series B
Last 12 Mo
4
Team
AS
Amy Schulman
Managing Partner
EM
Ellie McGuire
Partner
KP
Kim Png
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
58 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| KKash | Pre-Seed | $2M | Feb 2026 |
 EpiBiologics | Series B | $107M | Jan 2026 |
 Zag Bio | Series A | $80M | Oct 2025 |
 Cirrus Therapeutics | Seed | $11M | Oct 2025 |
 Noema Pharma | Series B | — | Dec 2024 |
 ByHeart | Growth | $95M | May 2024 |
 JIBE Inc. | Seed | $875K | Mar 2024 |
 Cohere Health | Series C | $50M | Feb 2024 |
 Vico Therapeutics B.V. | Series B | $60M | Jan 2024 |
 Triveni Bio Inc. | Series A | $92M | Oct 2023 |
 65LAB | Unknown | — | Oct 2023 |
| SSimon Data | Series D | $54M | Aug 2023 |
 Candesant Biomedical | Series B | $35M | Jun 2023 |
| PParatus Sciences | Series D | $100M | Feb 2023 |
 Jnana Therapeutics | Series C | $107M | Nov 2022 |
 FOLX Health | Series B | $30M | Oct 2022 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Podimetrics | Series C | $45M | Mar 2022 |
 Dewpoint Therapeutics | Series C | $150M | Feb 2022 |
 Freenome | Series D | $300M | Dec 2021 |
 Muna Therapeutics | Series A | $73M | Jul 2021 |
| ByHeart | Series B | $90M | Jul 2021 |
| CCubicPV | Series B | $25M | Jun 2021 |
| FFaro Health Inc. | Series A | $15M | Jun 2021 |
 Thirty Madison | Series C | $140M | Jun 2021 |
Page 1 of 3
Top Co-Investors
GV (Google Ventures)7 shared
D1 Capital Partners5 shared
F-Prime Capital5 shared
Invus5 shared
.406 Ventures4 shared
RA Capital Management4 shared
Kaiser Permanente Ventures4 shared
Section 324 shared
Flare Capital Partners4 shared
ARCH Venture Partners4 shared
Khosla Ventures4 shared
Perceptive Advisors3 shared
Bain Capital Life Sciences3 shared
Leaps by Bayer3 shared
Alexandria Venture Investments3 shared
Andreessen Horowitz3 shared
Cormorant Asset Management2 shared
Janus Henderson Investors2 shared
Novartis Venture Fund2 shared
T. Rowe Price Associates, Inc.2 shared
Last updated: 13 March 2026